Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial

To investigate efficacy and safety of St. John's wort (SJW) LI 160 in somatoform disorders. In a prospective, randomized, placebo-controlled, and double-blind parallel group study, 184 outpatients with somatization disorder (ICD-10 F45.0), undifferentiated somatoform disorder (F45.1), and somat...

Full description

Saved in:
Bibliographic Details
Published in:Psychosomatic medicine 2004-07, Vol.66 (4), p.538-547
Main Authors: Müller, Thomas, Mannel, Marcus, Murck, Harald, Rahlfs, Volker W
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Ambulatory Care
Clinical trials
Double-Blind Method
Drug Administration Schedule
Drug therapy
Female
Humans
Hypericum
Male
Mental disorders
Middle Aged
Phytotherapy
Placebos
Plant Preparations - therapeutic use
Prospective Studies
Psychiatric Status Rating Scales
Reproducibility of Results
Somatoform Disorders - diagnosis
Somatoform Disorders - drug therapy
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate efficacy and safety of St. John's wort (SJW) LI 160 in somatoform disorders. In a prospective, randomized, placebo-controlled, and double-blind parallel group study, 184 outpatients with somatization disorder (ICD-10 F45.0), undifferentiated somatoform disorder (F45.1), and somatoform autonomic dysfunction (F45.3), but not major depression, received either 300 mg of SJW extract LI 160 twice daily or matching placebo for 6 weeks. Six outcome measures were evaluated as a combined measure by means of the Wei Lachin test: Somatoform Disorders Screening Instrument--7 days (SOMS-7), somatic subscore of the HAMA, somatic subscore of the SCL-90-R, subscores "improvement" and "efficacy" of the CGI, and the global judgment of efficacy by the patient. In the intention to treat population (N=173), for each of the six primary efficacy measures as well as for the combined test, statistically significant medium to large-sized superiority of SJW treatment over placebo was demonstrated (p
ISSN:0033-3174
1534-7796
DOI:10.1097/01.psy.0000128900.13711.5b